Longeveron Inc. (LGVN) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Longeveron Inc.
Address
1951 NW 7th Avenue
Miami, FL 33136
United States of America (the)
Phone
305 909 0840
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
February 12, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Stephen H. Willard | Chief Executive Officer | 0 | 1961 |
| Joshua Michael Hare FACC | Co-Founder, Chief Science Officer & Executive Chairman | 523,009 | 1963 |
| Paul T. Lehr | General Counsel & Secretary | 674,931 | 1968 |
| Lisa Locklear | Chief Financial Officer, Executive Vice President & Treasurer | 675,003 | 1962 |
| Devin Blass | Chief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls | 0 | 1986 |
| Nataliya Agafonova | Chief Medical Officer | 0 | 1970 |
| Brian Rash | Vice President of Research & Discovery | 0 | N/A |
| Lisa McClain-Moss | Vice President of Manufacturing | 0 | 1971 |
Description
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
